Song Xu^1,2,3,4,5,*, Mengxin Lu^1,2,3,4,5, Zhonghua Yang^1,2,3,4,5, Hang Zheng^1,2,3,4,5

Canadian Journal of Urology, Vol.32, No.6, pp. 579-588, 2025, DOI:10.32604/cju.2025.063069 - 30 December 2025

Abstract Background: Many studies have evaluated the performance of fluorescence in situ hybridization (FISH) in detecting urothelial carcinoma, while few of them compared it in detecting bladder cancer (BC) vs. upper tract urothelial carcinoma (UTUC). This study aimed to determine and compare the FISH performance in detecting BC and UTUC. Methods: Data of patients with suspected urothelial carcinoma (UC) who accepted FISH from January 2021 to April 2023 were retrieved. The sensitivity and specificity of FISH in detecting BC and UTUC were determined and compared. Results: A total of 145 BC, 62 UTUC, and 170 non-UC patients were… More >

Lihao Zhang^1,2, Lin Cao^1,2, Lige Huang^1,2, Jie Wang^1,2, Jiabing Li^2,3,*

Canadian Journal of Urology, Vol.32, No.5, pp. 457-468, 2025, DOI:10.32604/cju.2025.067364 - 30 October 2025

Abstract Background: Studies have indicated an association between inflammatory factors (IFs) in the blood and the development of bladder cancer (BC). This study aimed to explore the correlation and clinical significance of IFs with the pathological grading of BC. Methods: A retrospective analysis was conducted on the preoperative blood routine results, postoperative pathological findings, and baseline information of 163 patients. Patients were divided into high-grade and low-grade groups based on pathological grading. Group comparisons and logistic regression analyses were performed using R software version 4.1.3 to explore the relationships between IFs and BC pathological grading. Results: The… More >

Azik Hoffman^1,2,*, Eyal Kochavi³, Gilad E. Amiel^1,2

Canadian Journal of Urology, Vol.32, No.5, pp. 423-432, 2025, DOI:10.32604/cju.2025.064740 - 30 October 2025

Abstract Objectives: Initial treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) has remained mostly unchanged in recent decades. Cryotherapy with CO₂ has been commonly used in medicine for many years. In this study, we present the results of a pre-clinical study aimed at developing a novel cryoablation device to treat superficial low-grade bladder lesions. Methods: Following initial technical and developmental studies, a rigid cryotherapy device was developed. A technical and efficacy assessment was conducted utilizing the porcine model. Overall, twenty-six ablation areas (up to four per animal) were evaluated. Following an initial routine cystoscopy, the bladder irrigation medium… More >

Liangju Peng^1,2, Tingting Cai^1,2, Peihang Xu^1,2, Cong Chen³, Qingzhi Xiang^1,2, Yiping Zhu^1,2, Dingwei Ye^1,2,*, Yijun Shen^1,2,*

Oncology Research, Vol.33, No.9, pp. 2463-2489, 2025, DOI:10.32604/or.2025.064331 - 28 August 2025

Abstract Background: Studies have reported the special value of PANoptosis in cancer, but there is no study on the prognostic and therapeutic effects of PANoptosis in bladder cancer (BLCA). This study aimed to explore the role of PANoptosis in BLCA heterogeneity and its impact on clinical outcomes and immunotherapy response while establishing a robust prognostic model based on PANoptosis-related features. Methods: Gene expression profiles and clinical data were collected from public databases. Spatial heterogeneity of cell death pathways in BLCA was evaluated. Consensus clustering was performed based on identified PANoptosis genes. Cell death pathway scores, molecular, and… More >

Arjun Pon Avudaiappan^*, Pushan Prabhakar, Hannah Baker, Mukesh K. Roy, Manuel Ozambela Jr, Christopher Gomez, Murugesan Manoharan

Canadian Journal of Urology, Vol.32, No.3, pp. 137-143, 2025, DOI:10.32604/cju.2025.064725 - 27 June 2025

Abstract Introduction: Radical cystectomy with pelvic node dissection remains the standard of care for muscle-invasive bladder carcinoma (MIBC); however, there is a growing interest in bladder preservation alternatives among the elderly population. Guidelines indicate that partial cystectomy (PC) combined with pelvic node dissection (LND) can be considered as an alternative in carefully selected individuals. Using the National Cancer Database, we analyzed the overall survival (OS) between PC with and without LND among octogenarians. Methods: We identified octogenarians with localized muscle-invasive bladder carcinoma (cT2-3N0M0) and urothelial histology who underwent PC with or without LND between 2004 and… More >

MOHAMMAD AMIN ELAHI NAJAFI^1,2,#, TAKUO MATSUKAWA^1,2,#, HIROSHI MIYAMOTO^1,2,3,*

Oncology Research, Vol.33, No.6, pp. 1255-1270, 2025, DOI:10.32604/or.2025.062142 - 29 May 2025

Abstract Sex hormones, including androgens and estrogens, are known to have widespread physiological actions beyond the reproductive system via binding to their cognitive receptors, members of the nuclear receptor superfamily that function as ligand-inducible transcription factors. Meanwhile, a growing body of evidence has indicated the involvement of androgen receptor, as well as estrogen receptors such as estrogen receptor-α and estrogen receptor-β, in the pathogenesis and growth of various types of malignancies, including urothelial cancer. Additionally, in bladder cancer, the activity of sex hormone receptors has been implicated in modulating sensitivity to conventional non-surgical therapy. These may More >

LUCIANA SABOYA^1,2, KEINI BUOSI¹, TIAGO SILVA², ELAINE CANDIDO¹, JOSIANE MORARI³, LICIO A. VELLOSO³, SHAHROKH F. SHARIAT^4,5,6,7, MARCUS V. SADI², LEONARDO O. REIS^1,8,9,*

Oncology Research, Vol.33, No.6, pp. 1495-1503, 2025, DOI:10.32604/or.2025.061812 - 29 May 2025

Abstract Objective: To determine the safety and the role of modulating cytokines and proteases in the immune response to intravesical Bacillus Calmette-Guérin (BCG) when primed with systemic intradermal BCG. Methods: Phase 1 and mechanistic longitudinal, prospective, single-blind randomized study (NCT04806178). Twenty-one non-muscle invasive urothelial bladder cancer patients undergoing intravesical adjuvant BCG after transurethral resection of bladder tumor (TURBT) in a teaching hospital between September 2021 and April 2023 were randomized to 0.1 mL of intradermal BCG vaccine or placebo (0.9% saline) administered 15 days before the start of intravesical BCG therapy. Blood samples were evaluated mechanistically… More >

THAINá RODRIGUES^1,2, PATRíCIA CANDIDO^1,3, FERES CAMARGO MALUF¹, POLIANA ROMãO¹, CAROLINA MIE MIOSHI¹, VANESSA RIBEIRO GUIMARãES¹, JULIANA ALVES DE CAMARGO¹, KARINA SERAFIM DA SILVA^1,4, GABRIEL ARANTES DOS SANTOS¹, IRAN AMORIM SILVA¹, KATIA RAMOS MOREIRA LEITE¹, WILLIAM C. NAHAS⁵, SABRINA T. REIS^1,3, RUAN PIMENTA^1,6, NAYARA IZABEL VIANA^1,7,*

Oncology Research, Vol.33, No.6, pp. 1377-1382, 2025, DOI:10.32604/or.2025.055306 - 29 May 2025

Abstract Objectives: Bladder Cancer (BC) is one of the most commonly diagnosed malignancies worldwide, with high rates of mortality and morbidity. It can be classified as non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC), with radical cystectomy being the treatment for MIBC, which significantly reduces quality of life. MicroRNAs (miRs) act as critical genetic regulators, with both oncogenic and tumor-suppressive roles. MiR-10a is described as a tumor suppressor in various neoplasms, but its role in BC is controversial. This study aims to assess the activity of miR-10a in cellular invasion and proliferation in two… More >

Badrinath R. Konety^1,*, Yair Lotan², Amanda Myers³

Canadian Journal of Urology, Vol.32, No.1, pp. 29-36, 2025, DOI:10.32604/cju.2025.064710 - 20 March 2025

Abstract Introduction: Non–muscle-invasive bladder cancer (NMIBC) is a common malignancy worldwide. While Bacillus Calmette-Guérin (BCG) is standard of care for treatment for most patients with high-risk NMIBC, many will either not respond to BCG initially or will eventually develop BCG-unresponsive disease. A treatment option in BCG-unresponsive disease is nadofaragene firadenovec-vncg (Adstiladrin), a nonreplicating adenoviral vector–based gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of adults with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors. Objective: To review safety outcomes of participants who received the FDA-approved dose… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.4, pp. 993-993, 2025, DOI:10.32604/or.2024.056915 - 19 March 2025

Abstract This article has no abstract. More >